High-intensity focused ultrasound (HIFU) achieves effective long-term prostate cancer control in patients with low- and intermediate-risk tumors, French and German researchers reported in European Urology (2008;53:1194-1203).


They studied 140 patients treated with early HIFU devices. The actuarial biochemical failure-free survival rates at five and seven years were 77% and 69%, respectively.

Continue Reading


The actuarial disease-free survival rates were 66% and 59%, respectively.